TOPLINE: Berberine ursodeoxycholate (HTD1801) showed potential as a treatment option for patients with type 2 diabetes (T2D), with significant reductions in A1c and fasting plasma glucose levels. The treatment was well tolerated, with mild to moderate adverse effects observed. METHODOLOGY: Antidiabetic medications targeting metabolic risk factors along with inducing glycemic control are in demand. HTD1801 […]
The post Berberine Ursodeoxycholate Reduces A1c in Type 2 Diabetes first appeared on News Health.
Author : News Health
Publish date : 2025-03-10 11:39:00
Copyright for syndicated content belongs to the linked Source.